The risk of developing CS increases with age.[1,3,35,36] Age is also a potent predictor of mortality following acute MI.[37,38] Consequently, although the age-adjusted case fatality rate following acute MI has fallen dramatically over the past three decades, the incidence of MI, incidence of CS, and the unadjusted mortality rate following MI have remained relatively constant. Present demographics will ensure an increasing baseline risk in future MI populations. The economic and health care demands arising from this are staggering. Despite the advances in primary prevention, research in CS should remain a high priority. Novel modalities to preserve ischemic myocardium need to be studied. One approach that may warrant investigation in CS is the use of glucose-insulin-potassium infusions. In the interim, our clinical experiences in the SHOCK trial will help guide present available therapy.
Address for correspondence: Venu Menon, MD, Assistant Director of Cardiac Research, Division of Cardiology, St. Luke's-Roosevelt Hospital Center, 1111 Amsterdam Avenue, New York, NY 10025 E-mail: email@example.com
CHF. 2003;9(1) © 2003 Le Jacq Communications, Inc.
Cite this: Cardiogenic Shock: A Summary of the Randomized SHOCK Trial - Medscape - Jan 01, 2003.